150
Participants
Start Date
February 20, 2025
Primary Completion Date
September 1, 2025
Study Completion Date
September 7, 2025
Zinc Supplementation
Participants assigned to zinc-containing arms will receive oral zinc gluconate supplementation (78 mg twice daily) for 8 weeks. This intervention aims to evaluate the effect of zinc in preventing and reducing the severity of regorafenib-induced hand-foot skin reaction (HFSR).
Clobetasol Propionate 0.05% Cream
Participants assigned to clobetasol-containing arms will receive topical clobetasol propionate 0.05% cream, applied twice daily to the palms and soles for 8 weeks. This intervention aims to assess the efficacy of clobetasol in preventing regorafenib-induced HFSR.
Bursa Uludağ University Hospital, Bursa
Dicle University Hospital, Diyarbakır
Necmettin Erbakan University Meram Faculty of Medicine Hospital, Konya
Sakarya University Hospital, Sakarya
Tekirdağ Namık Kemal University Hospital, Tekirdağ
Karadeniz Technical University Hospital, Trabzon
Van Yüzüncü Yıl University Dursun Odabaş Hospital, Van
Ankara Etlik City Hospital, Ankara
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara
Gazi University, Ankara
Afyonkarahisar University of Health Sciences Hospital, Afyonkarahisar
Ankara University Faculty of Medicine Hospital, Ankara
Hacettepe University Faculty of Medicine Hospital, Ankara
Gazi University
OTHER